Autotaxin and Breast Cancer: Towards Overcoming Treatment Barriers and Sequelae

After a decade of intense preclinical investigations, the first in-class autotaxin inhibitor, GLPG1690, has entered Phase III clinical trials for idiopathic pulmonary fibrosis. In the intervening time, a deeper understanding of the role of the autotaxin–lysophosphatidate (LPA)–lipid phosphate phosph...

Descripción completa

Detalles Bibliográficos
Autores principales: Benesch, Matthew G. K., Tang, Xiaoyun, Brindley, David N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072337/
https://www.ncbi.nlm.nih.gov/pubmed/32041123
http://dx.doi.org/10.3390/cancers12020374

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072337/
https://www.ncbi.nlm.nih.gov/pubmed/32041123
http://dx.doi.org/10.3390/cancers12020374

Ejemplares similares